However, a plausible explanation for this phenomenon is that hypomethylating agents like decitabine may reverse an unbalanced DNA methylation in TP53-mutated AML cells because normal p53 suppresses DNA methylation by up-regulating TET1/2 components of the demethylation machinery [17]. This evidence concerns the gene TP53 and acute myeloid leukemia.